Mangalam Drugs & Organics Limited (NSE:MANGALAM)
India · Delayed Price · Currency is INR 29.87
+0.46 (1.56%)
May 25, 2026, 10:34 AM IST
Mangalam Drugs & Organics Revenue
In the fiscal year ending March 31, 2026, Mangalam Drugs & Organics had annual revenue of 2.33B INR, down -26.66%. Mangalam Drugs & Organics had revenue of 673.77M in the quarter ending March 31, 2026, a decrease of -7.42%.
Revenue
2.33B
Revenue Growth
-26.66%
P/S Ratio
0.20
Revenue / Employee
4.85M
Employees
480
Market Cap
474.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.33B | -846.80M | -26.66% |
| Mar 31, 2025 | 3.18B | -497.78M | -13.55% |
| Mar 31, 2024 | 3.67B | -28.42M | -0.77% |
| Mar 31, 2023 | 3.70B | -806.66M | -17.89% |
| Mar 31, 2022 | 4.51B | 708.84M | 18.65% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nectar Lifesciences | 16.70B |
| Sigachi Industries | 4.85B |
| Balaxi Pharmaceuticals | 2.76B |
| Valiant Laboratories | 2.37B |
| Bafna Pharmaceuticals | 1.47B |
| Alpa Laboratories | 1.14B |
| Vaishali Pharma | 1.14B |
| Par Drugs and Chemicals | 1.08B |